The VECTOR Trial

Tolerability of Solifenacin 5 mg Once Daily Versus Oxybutynin IR 5 mg Three Times Daily: Results of the VECTOR Trial

Sender Herschorn,* Lynn Stothers, Kevin Carlson, Blair Egerdie, Jerzy B. Gajewski, Peter Pommerville, Jane Schulz, Sidney Radomski, Harold Drutz, Jack Barkin, Fran Paradiso-Hardy

From the Department of Surgery/Urology, University of Toronto, Toronto, ON, Canada (SH, SR), University of British Columbia, Bladder Care Centre, Vancouver, BC, Canada (LS), Division of Urology, University of Calgary, Calgary, AB, Canada (KC), Urology Associates/Urologic Medical Research, Kitchener, ON, Canada (BE), Department of Urology, Dalhousie University, Halifax, NS, Canada (JBG), Can-Med Clinical Research Inc., Victoria, BC, Canada (PP), Department of Obstetrics and Gynecology, Royal Alexandra Hospital, University of Alberta, Edmonton, AB, Canada (JS), Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada (HD), Department of Surgery, University of Toronto, Toronto, ON, Canada (JB), and Astellas Pharma Canada, Markham, ON, Canada (FP-H)

* Correspondence: Sender Herschorn, Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Room A309, Toronto, ON M4N 3M5, Canada (telephone: +1 416-480-4733; FAX: +1 416-480-6121; e-mail: s.herschorn@utoronto.ca).